ResMed Announces SaaS Leadership Change
ResMed (NYSE: RMD) announces the promotion of Bobby Ghoshal to President of its SaaS business, effective immediately. This change is aimed at accelerating digital transformation and growth within the company’s software-as-a-service sector. Ghoshal, previously serving as Chief Technology Officer, brings over 25 years of industry experience. Raj Sodhi will depart from his role on September 1, after contributing significantly to ResMed's digital health strategy. CEO Mick Farrell emphasizes the need for innovative digital solutions to enhance healthcare delivery and reach their goals for 2025.
- Bobby Ghoshal's promotion is expected to drive growth in ResMed's SaaS business.
- Ghoshal’s background and experience in technology and leadership are seen as assets in advancing ResMed’s digital strategy.
- Raj Sodhi's departure may create a gap in leadership continuity and experience.
Change intended to drive rapid digital transformation, leverage full scale of cloud-connected technology platforms, and accelerate growth of ResMed’s SaaS business
SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), today announced the promotion of Bobby Ghoshal to President of ResMed’s SaaS business, effective immediately. Raj Sodhi will be leaving full-time employment at ResMed, effective September 1.
Bobby has over 25 years of experience across medical and technology industries, most currently serving as ResMed’s Chief Technology Officer (CTO), with strong experience building and leading high-performing teams to accelerate the adoption of digital platforms across enterprises. From February 2016 until April 2018, Bobby served as chief operating officer for Brightree, a ResMed-owned provider of cloud-based software-as-a-service for out-of-hospital care. ResMed will commence a search process for a new CTO immediately; Bobby will remain in the CTO role until a replacement is found.
“As we look ahead to 2025, we believe the future of healthcare is outside the hospital and we have an amazing mission to improve over 250 million lives,” said Mick Farrell, ResMed’s CEO. “We must accelerate our efforts to bring software technology, along with digital and commercial innovation, to these care settings. Digital solutions, scalable digital platforms, and software embedded into our customers’ workflows are critical to our growth strategy – Bobby’s experience as ResMed’s CTO, his hands-on experience with Brightree, and his strong background across many industries makes him the right leader to accelerate our SaaS business to meet our goals for 2025 and beyond.”
“I’d like to thank Raj for the incredible work he’s done over the past nine years at ResMed,” continued Farrell. “Raj played an important role in developing the healthcare informatics function at ResMed, a function that helped to transform the company on our path to becoming the leader in digital health. He also helped to craft the SaaS strategy and lead multiple acquisitions that established the foundation for us to scale and grow our SaaS business in home medical equipment, skilled nursing facilities, home health, hospice, private duty homecare, and beyond.”
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
| For investors | For media |
| Amy Wakeham | Jayme Rubenstein |
| +1 858.836.5000 | +1 858.836.6798 |
| investorrelations@resmed.com | news@resmed.com |
FAQ
What is the significance of Bobby Ghoshal's promotion at ResMed?
What are the expected impacts of Raj Sodhi leaving ResMed?
How does ResMed plan to achieve its goals for 2025?
What experience does Bobby Ghoshal bring to his new role?
